Leonard Frank X's Form 4 filing
NovoCure Ltd (NVCR) · filed Mar 5, 2024
- Accession no.
- 0001562180-24-002247
- Filed
- Mar 5, 2024
- Trade date
- Mar 1-4, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $40.4K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Leonard Frank XCIK 0001822879 | Officer (EVP, Pres., Novocure Oncology) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 1, 2024 | Ordinary Shares | SSaleDisposed | −1,679 | $16.03 | −$26,914.37 | 160,938 | Direct | |
| Mar 4, 2024 | Ordinary Shares | SSaleDisposed | −840 | $16.01 | −$13,448.4 | 160,098 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.